Immunization with AZD1222 COVID-19 increases CVT risk
According to a study published online in JAMA Network Open on June 14, the rates of clinic contraction for cerebrovascular illness and coagulation disease are heightened following AZD1222 COVID-19 immunization, particularly for thrombocytopenia and cerebral venous thrombosis.
Dr. Dag Berild and coworkers from the Norwegian Institute of Public Health in Oslo, Norway, conducted a self-controlled case series study examining mRNA-1273, BNT162b2, and AZD1222 jabs’ effect on thrombocytopenic and thromboembolic events after vaccination using information from Denmark, Finland, and Norway’s federal registries.
The relative rate (RR) of the test subjects to clinic contacts were examined for cerebrovascular disease, coagulation disorder, or coronary artery disease within a twenty-eight-day period before and after vaccination.
The investigators found 265,339 clinic contacts, of which 44 percent were for coronary artery disease, 21 percent were for coagulation defects, and 35 percent were for cerebrovascular diseases.
The RR of coronary artery disease was heightened in the 28 days following mRNA-1273 immunization but remained fairly stable after BNT162b2 or AZD1222 immunization. After receiving all 3 shots, the RR of coagulation problems was higher.
Also, after all the 3 vaccinations, the cerebrovascular illness rate was heightened. After AZD1222 administration, high ratios of thrombocytopenia (4.29) and cerebral venous thromboembolism (12.04) were noticed.
“Although mRNA-1273 and BNT162b2 jabs heightened the incidence of several thrombocytopenic and thromboembolic sequelae, these increased rates were minimal compared to what was detected following AZD1222 shot,” the researchers state.